尋常型天皰瘡：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 預計西班牙尋常型天皰瘡市場將從 2025 年的 1,200 萬美元成長到 2035 年的 2,600 萬美元。
• 推動市場成長的因素如下：
• 生物製藥和標靶免疫療法的應用日益廣泛
• 改善診斷和疾病管理
• 未來的成長取決於提供安全性更高、療效更持久的治療方法。

尋常型天皰瘡概述

尋常型天皰瘡是一種罕見但可能危及生命的自體免疫水痘疾病，其特徵是抗體攻擊負責連接皮膚細胞的蛋白質，導致皮膚和黏膜出現疼痛的水痘和糜爛。如果不及時治療，病情會廣泛擴散。在現代治療的大部分歷史中，治療方法依賴大劑量皮質類固醇和各種免疫抑制劑的聯合應用。雖然這種方法可以控制病情，但通常會帶來嚴重的長期副作用。然而，隨著B細胞清除抗體療法成為首個獲準用於治療該疾病的生物製藥，情況發生了巨大變化。這是數十年來治療進展緩慢後的真正突破，目前，基於臨床試驗結果顯示其療效顯著優於皮質類固醇單藥治療，B細胞清除抗體療法已被推薦為與皮質類固醇聯合使用的一線療法。在抗體介導的自體免疫疾病中，尋常型天皰瘡的特異性在於，這種成功難以複製。由於在密切相關的疾病中取得成功的、具有全新作用機制的藥物在這裡沒有顯示出類似的效果，因此人們重新對臨床試驗結果差異的原因產生了興趣。

主要亮點

• 據預測，德國尋常型天皰瘡（PV）病例數將從 2025 年的 7,972 例增加到 2035 年的 11,793 例。
• 尋常型天皰瘡是一種罕見的自體免疫水痘疾病，會導致皮膚和黏膜出現疼痛性病灶。
• 儘管免疫抑制療法已經問世，但疾病復發和治療相關的副作用仍然是重大挑戰。
• 目前仍存在大量未被滿足的、能夠實現疾病持續控制的標靶治療需求。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Cabaletta Bio

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要療法－概述及關鍵意見領袖見解
• 新興療法
• 重點
• 值得關注的後期新興療法—概述、市場上市預期和關鍵意見領袖的觀點。
• 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

• 尚未滿足的主要需求及其透過新興療法實現的潛力。
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Pemphigus Vulgaris Market Outlook

Thelansis's "Pemphigus Vulgaris Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pemphigus Vulgaris treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Pemphigus Vulgaris Overview

Pemphigus vulgaris is a rare, potentially life-threatening autoimmune blistering disease in which antibodies attack proteins responsible for holding skin cells together, causing painful blistering and erosion across the skin and mucous membranes that can become extensive without treatment. For most of the modern treatment era, care relied on high-dose corticosteroids paired with various immunosuppressants, an approach that could control the disease but often at the cost of significant long-term side effects. That changed when a B-cell depleting antibody therapy became the first biologic approved for the condition, a genuine milestone after decades without a major treatment advance, and it is now recommended alongside corticosteroids as first-line therapy based on trial evidence showing meaningfully better outcomes than steroids alone. What makes pemphigus somewhat unusual within antibody-mediated autoimmune disease is that this success has been difficult to replicate, with newer mechanisms that succeeded in closely related conditions failing to show similar benefit here, prompting renewed interest in why trial outcomes diverge.

Key Highlights

• In Germany, prevalent Pemphigus Vulgaris (PV) cases are projected to increase from 7,972 in 2025 to 11,793 by 2035.
• Pemphigus Vulgaris is a rare autoimmune blistering disease causing painful skin and mucosal lesions.
• Despite available immunosuppressive therapies, disease relapse and treatment-related adverse effects remain major challenges.
• Significant unmet need remains for targeted therapies that provide durable disease control.

Market Overview

• The Spain Pemphigus Vulgaris market is projected to grow from $12M in 2025 to $26M by 2035.
• Market growth is driven by:
• Increasing adoption of biologic and targeted immunotherapies
• Improved diagnosis and disease management
• Future growth will depend on therapies offering sustained remission with improved safety profiles.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Cabaletta Bio

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)